Objective: Depression and anxiety are highly prevalent in patients with cardiovascular disease (CVD) and influence their mental wellbeing and CVD prognosis. The primary objective was to assess the effectiveness of cognitive behavioral therapy (CBT) for depression and anxiety in patients with CVD. Secondary objectives were to assess the impact of CBT on cardiovascular mortality, cardiovascular events, patient satisfaction, and quality of life. Methods: MEDLINE, PsycINFO, CINAHL, CENTRAL, and alternative sources were searched for randomized controlled trials and observational studies with a control. Studies were required to assess CBT in coronary heart disease, acute coronary syndrome, atrial fibrillation, or postmyocardial infarction patients, with anxiety and/or depression. Studies were independently screened by two reviewers and critically appraised using the Cochrane Risk of Bias tool. The random-effects model was used to pool standardized mean differences (SMD). Results: Twelve randomized controlled trials were included. At follow-up, depression (SMD = −0.35, 95% confidence interval [CI] = −0.52 to −0.17, p < .001, I 2 = 59%) and anxiety (SMD = −0.34, 95% CI = −0.65 to −0.03, p = .03, I 2 = 71%) scores were significantly lower in CBT patients compared with controls. Change in mental health quality of life (SF-12) was also significantly greater for CBT patients, compared with controls (mean difference = 3.62, 95% CI = 0.22 to 7.02, p = .04, I 2 = 0%). No differences in patient satisfaction or cardiovascular events were evident between CBT and control groups. Among the study reports included in this meta-analysis, data specific to cardiovascular mortality were not reported. Conclusions: Cognitive behavioral therapy seems to be an effective treatment for reducing depression and anxiety in patients with CVD and should be considered in standard clinical care.
INTRODUCTION
C ardiovascular disease (CVD) is the leading cause of mortality worldwide and responsible for almost one third of all deaths (1) . European guidelines recognize depression and anxiety as important factors that contribute to the risk of developing CVD and a worse CVD prognosis; however, the relationship between mental illness and CVD has received less recognition globally (2) . Mechanisms linking anxiety and depression with CVD are unconfirmed; however, biological and behavioral processes have been proposed (3, 4) . Both anxiety and depression have been implicated in the dysfunctional activity of the autonomic nervous system and hypothalamic-pituitary-adrenal axis, which affect the cardiovascular system (3, 4) . Poor life-style behaviors such as smoking, inactivity, and low treatment adherence, which increase the CVD risk, are also common in anxious and depressed patients (4) .
Prevalence of depression and anxiety among patients with CVD is up to three-fold higher than in the general population (5, 6) . Changes in quality of life (QoL) and the impact of a chronic disease can significantly affect mental well-being. Among patients with coronary heart disease (CHD), approximately 20% meet the DSM criteria for major depression, and this can impact on disease
METHODS
This systematic review and meta-analysis was prospectively registered with the PROSPERO database of systematic reviews (CRD42017057723) (21) and conducted in accordance with the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines (22) .
Criteria for Considering Studies for the Review
Randomized controlled trials (RCTs) and observational studies with a concurrent control group were eligible for inclusion. Studies were required to have a baseline and at least one follow-up measure for depression and/or anxiety. Access to the full-text publication was a requirement. There were no date or language restrictions.
Participants
Eligible participants were those with CVD (CHD, ACS, AF, or post-MI) and depression or anxiety. Anxiety or depression was defined as either a clinical diagnosis (International Classification of Diseases (23) , DSM (24), or similar) or the presence of anxious and/or depressive symptoms (≥ a predefined cut-off on a validated questionnaire). Studies of ICD and heart failure patients were excluded because recent previous systematic reviews have assessed the effectiveness of CBT for depression and/or anxiety in these patients (15, 17) .
Interventions
Interventions described as CBT or based on CBT principles were eligible for inclusion, where patients were taught to monitor their mood by identifying and challenging the thoughts and behaviors at the source of their depressive or anxious state. This could have been referred to as CBT, cognitive therapy, or behavioral therapy. However, interventions that solely used the principles of cognitive therapy or behavioral therapy alone were excluded. "Third-wave" CBT was also excluded because some forms only focus on one traditional CBT principle. Other psychotherapies (e.g., cognitive analytical therapy, psychodynamic psychotherapy, and interpersonal psychotherapy) were excluded. Studies that investigated CBT as one element within a mixed intervention package were not included, although CBT with an adjunctive antidepressant as recommended by NICE was accepted (12) .
Comparators
Eligible comparators were medications, usual care (including other psychological therapies), waiting list control, or no treatment.
Outcomes
The primary outcome was a reduction in anxiety and/or depression in patients with CVD after CBT. Patients still classified as depressed and/or anxious according to a validated questionnaire and those no longer meeting the clinical diagnosis at follow-up were also reported. Secondary outcomes included cardiovascular events, cardiovascular mortality, patient satisfaction, and QoL.
Search Strategy
The search strategy was developed by the research team and checked by an information specialist before execution (see Figure S1 , Supplemental Digital Content, http://links.lww.com/PSYMED/A498). Key words such as "CBT," "heart diseases," "anxiety," and "depression" were used. MEDLINE, PsycINFO, CINAHL, and the Cochrane Central Register of Controlled Trials (CENTRAL) were searched from inception to February 10, 2017, for relevant studies. No language restrictions were applied.
Reference lists of included studies were manually searched, and citation searches were completed to identify other relevant articles. Grey literature was addressed by contacting the leading authors of included articles and key opinion leaders for unpublished data. Clinicaltrials.gov was searched for unpublished protocols of RCTs from 2007 to 2017. Conference proceedings of the European Society of Cardiology, American Heart Association, and American College of Cardiology 2015-2017 were also searched.
Study Selection
Study selection was undertaken by two independent reviewers (J.R., M.H.). Articles with irrelevant titles and abstracts were excluded and those deemed eligible or unclear were further assessed in their full texts. Original authors were contacted for additional information when necessary for eligibility assessments. Disagreements over study eligibility were resolved by discussion and adjudication by a third reviewer (D.L.).
Data Extraction
Using a standardized, prepiloted data extraction form, data were extracted by one reviewer (J.R.), with 25% checked by another reviewer (M.H.). Information regarding the study characteristics (study design and sample size), participants (age, sex, psychiatric assessment, and CVD diagnosis), intervention (mode of delivery, duration, frequency, providers, and follow-up points), and comparator were gathered. For the primary outcome, mean differences and standard deviations for anxiety and depression scores between baseline and follow-up and the proportion still classified as depressed and/or anxious at follow-up were extracted. The proportion no longer meeting the clinical diagnosis for anxiety and/or depression at follow-up was noted. For the secondary outcomes, the proportions of patients experiencing cardiovascular events and death were collected in addition to mean differences and standard deviations for patient satisfaction (on a Likert scale) and QoL (on a validated questionnaire) between baseline and follow-up.
Original authors were contacted when information was unclear or missing. If changes in scores between baseline and follow-up were unavailable and could not be imputed, follow-up scores were used as an alternative outcome. Only findings reported post-CBT were extracted.
Four authors (25) (26) (27) (28) were contacted for missing standard deviations; however, only one author provided these data (27) . Six authors provided data on an eligible study subgroup of their population (29) (30) (31) (32) (33) (34) .
Risk of Bias Assessment
Two reviewers independently assessed the risk of bias (RoB) using the Cochrane RoB tool (35) for RCTs (all included studies were RCTs), consisting of the following six domains: random sequence generation; allocation concealment; blinding of participants, personnel, and outcome assessors; selective reporting; and other sources of bias. RoB was assigned as "high," "low," or "unclear" for each domain.
Data Synthesis
For anxiety, depression, patient satisfaction, and QoL outcomes, attempts were made to report change from baseline scores. If these data were not reported and could not be provided by study authors, imputation was attempted. However, the correlation coefficients calculated for anxiety, depression, and QoL were 0.5 or less or were too different to average, and therefore, follow-up scores were used as an alternative outcome, as recommended by Cochrane (36) . Standardized mean differences (SMD) and 95% confidence intervals (CIs) were calculated for continuous outcomes when data were measured using different scales. When outcomes were measured using the same scales, mean differences and 95% CIs were calculated. The proportions experiencing continued depression and/or anxiety (according to a validated questionnaire), cardiovascular death, cardiovascular event (s), and those no longer meeting a clinical diagnosis of depression and/or anxiety at follow-up were each summarized with odds ratios and 95% CIs.
Effect estimates were pooled using RevMan 5.3. DerSimonian and Laird random-effects method (36) was used when outcome scales differed between studies and standardized mean differences were used; when outcomes used the same scales in analyses, the fixed-effects model was used when pooling mean differences. Heterogeneity was assessed by observing the overlap of CIs on the forest plots and the I 2 value, with metaanalysis deemed inappropriate if there was considerable heterogeneity (I 2 ≥ 75%) (36) . When studies had multiple trial arms, the CBT intervention was compared with usual care. If outcomes were measured at different time points, the first outcome measure reported post-CBT was used in the metaanalysis. If studies reported multiple depression scores from different scales, the most common scale used by other eligible studies was chosen when pooling effect estimates to minimize heterogeneity.
Publication Bias
Publication bias was assessed using a funnel plot and Egger's test when outcomes included 10 studies or more.
Risk of Bias Across Studies (Quality Assessment)
Quality of the outcomes was assessed using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) considerations (37) .
Subgroup Analyses
Prespecified subgroup analyses were conducted for each CVD (e.g., CHD, AF, etc) where data were available, the mode of CBT delivery, and different lengths of follow-up. Study data on postcoronary artery bypass grafting (CABG) participants were included within the CHD subgroup analysis (a CHD history was assumed). Subgroup analyses for the mode of delivery (face-to-face, telephone, and mixed-method sessions), length of CBT course (short: 0-300 minutes, medium: 301-600 minutes, and long: >600 minutes), and length of follow-up (short-term: baseline to ≤3 months, medium-term: >3 months but ≤6 months, and long-term: >6 months) were completed.
Sensitivity Analyses
Sensitivity analyses were undertaken for studies with clinically diagnosed anxiety and/or depression versus no clinical diagnosis and for the primary outcomes excluding studies with a high RoB. A sensitivity analysis comparing RCTs versus observational studies was planned, but all included studies were RCTs. Further sensitivity analyses were completed for all studies versus no US trials and for all studies excluding the ENhancing Recovery in Coronary Heart Disease patients trial.
RESULTS

Study Selection
Searches identified 2115 articles ( Figure 1 ). After the removal of duplicates (n = 141), the titles and abstracts of 1974 articles were independently assessed for eligibility by two reviewers. Of these, 117 articles were deemed potentially relevant and assessed for eligibility in their full texts; 107 articles were excluded and two studies were on-going (CBT-AF (ISRCTN33129243) (38) and U-CARE Heart trial (NCT01504191) (39) ). Reviewers' agreement was 96.7%. Twelve articles were included, of which 2 were identified from reference lists of included studies (28,31) and 2 through citation searches (26, 32) .
Characteristics of the Included Studies
All included studies were RCTs and in English, conducted in the US (n = 7) (26-32), Germany (n = 2) (25,40), Australia (n = 2) (33, 41) , and the United Kingdom (n = 1) (34) ( Table 1) .
Participants
Participants were CHD (6 studies) (25) (26) (27) 32, 34, 40) , ACS (4 studies) (28, 30, 31, 41) , or post-MI (1 study) (29) patients, and one study was a mixed CVD group (33) . Studies recruited participants based on anxiety and/or depression (3 studies) (26, 28, 34) , depression alone (8 studies) (25, 27, (29) (30) (31) (32) (33) 41) , or anxiety alone (1 study) (40) . Eight studies recruited participants using a validated questionnaire (26, 28, 30, 31, 33, 34, 40, 41) , one used a formal clinical diagnosis (29) , and three used a combination (25, 27, 32) . Participants tended to be male (38.5%-87.5%), older than 60 years (mean = 55.6-64.2 years), and of white ethnicity. Study sample sizes ranged from 43 to 1332 participants.
Interventions
CBT was the named intervention in eight studies (25) (26) (27) (28) (29) 32, 33, 41) , and four studies described interventions based on CBT principles (30, 31, 34, 40) . Adjunctive antidepressants were offered in three studies (29) (30) (31) . CBT was delivered through face-to-face (7 studies) (25) (26) (27) 29, 32, 33, 40) , mixed-method (3 studies) (30, 31, 34) , or telephone (2 studies) (28, 41) sessions; all studies delivered four sessions or more. CBT was provided by psychologists (5 studies) (26, 28, 33, 40, 41) , psychotherapists (3 studies) (25, 29, 31) , mixed groups of healthcare professionals (2 studies) (27, 30) , and trained nurses (2 studies) (32, 34) .
Comparator
All comparators were usual/standard care, except in two studies, which either provided a brief intervention of information and feedback on baseline assessments (also received by the intervention group) or provided no intervention (33, 40) . Studies described usual care as dependent on the patient's primary care physician (30) (31) (32) 41) , and standard care involved identification of risk factors and advice on risk reduction (34) or booklets on coping with CVD (28).
Outcomes
Baseline and follow-up scores for anxiety were available in nine studies (25) (26) (27) (28) (31) (32) (33) (34) 40) and depression in 12 studies (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) 40, 41) . Four depression scales and five anxiety scales were used at various time points (1-12 months) to measure depression and anxiety (Table 2) . Four studies reported the proportion of participants achieving remission of depression at follow-up; the proportion still depressed at follow-up was calculated (27, (31) (32) (33) . One study reported the proportion of participants no longer meeting a clinical diagnosis of depression at follow-up (32) . No studies published cardiovascular mortality data for participants eligible for inclusion in this review; however, two studies recorded cardiovascular events (nonfatal MI or hospitalization for unstable angina) (30, 31) . Two studies reported changes in patient satisfaction between baseline and follow-up (30, 34) . Participant QoL was available in five studies (26, 27, 31, 34, 41) and was assessed as physical or mental QoL (SF-12) separately or the sum of the QoL.
Risk of Bias Within Studies
Because of the nature of CBT, all studies had a high RoB for personnel and participant blinding. Of the 12 included studies, a high RoB was assigned to three for incomplete outcome data (25, 28, 40) , two for other biases (28, 29) , and one for selective reporting (29) (Figure 2 ). An unclear RoB was assigned to four studies for allocation concealment (26, 28, 32, 40) and to six studies (25, 26, 28, (32) (33) (34) for selective reporting because protocols were unavailable. Sensitivity analyses of the primary outcomes were conducted for studies without a high RoB for the following domains: blinding of outcome assessment, incomplete outcome data, selective reporting, and other bias. The domains listed were those with studies rated as a high RoB. Sensitivity analyses demonstrated that the inclusion of studies with a high RoB did not significantly influence the primary outcomes (data not shown).
Effectiveness of CBT for Depression and Anxiety
The pooled depression follow-up scores from all 12 studies included 2254 participants (25) (26) (27) (28) (29) (30) (31) (32) (33) (34) 40, 41) . Depression follow-up scores were significantly lower in CBT patients than in controls (SMD = −0.35, 95% CI = −0.52 to −0.17, p < .001, I 2 = 59%) ( Figure 3A) . Compared with controls, fewer CBT participants remained depressed after the intervention (odds ratio [OR] = 0.29, 95% CI = 0.12 to 0.69, p = .005, I 2 = 62%) ( Figure 3B ). One study reporting the proportion of participants no longer meeting a clinical diagnosis of depression found that the CBT group had significantly fewer participants (31%) no longer meeting the diagnosis for depression compared with the controls (83%) (OR = 0.10, 95% CI = 0.03 to 0.36, p < .001) (32).
The pooled anxiety follow-up scores from nine studies included 605 participants (25) (26) (27) (28) (31) (32) (33) (34) 41) . Anxiety was significantly lower in CBT patients than in controls; however, substantial heterogeneity was present (SMD = −0.34, 95% CI = −0.65 to −0.03, p = .03, I 2 = 71%) ( Figure 4 ).
Cardiovascular Mortality
No studies published cardiovascular mortality data for depressed or anxious patients with CVD. One trial had subgroup data for depressed only patients with CVD, but this was not accessible to the authors for inclusion in this review (29) .
Cardiovascular Events
Two studies including 260 participants reported cardiovascular events (30, 31) . The pooled scores showed fewer cardiovascular events in CBT patients compared with the controls; however, this was not statistically significant (OR = 0.80, 95% CI = 0.33 to 1.93, p = .62, I 2 = 0%).
Patient Satisfaction
Two studies (130 participants) provided a change in patient satisfaction between baseline and follow-up (30, 34) . Pooled scores demonstrated greater patient satisfaction in favor of CBT compared with controls; however, this was not statistically significant (SMD = 0.11, 95% CI = −0.29 to 0.51, p = .28, I 2 = 16%).
Quality of Life
A nonsignificant difference between the CBT and control groups was observed for the change in physical health QoL (SF-12) (MD = 2.59, 95% CI = −0.41 to 5.60, p = .09, I 2 = 0%); however, the change in mental health QoL (SF-12) was significantly better in CBT patients compared with controls (MD = 3.62, 95% CI = 0.22 to 7.02, p = .04, I 2 = 0%). Overall, QoL at follow-up was greater in CBT patients compared with controls, but this was not significant (SMD = −0.10, 95% CI = −0.47 to 0.26, p = .58, I 2 = 47%). 
Publication Bias
A visual assessment of the funnel plot for depression follow-up highlighted little asymmetry (see Figure S2 , Supplemental Digital Content, http://links.lww.com/PSYMED/A498). The Egger's test for publication bias was not significant (0.034, 95% CI = −1.82 to 1.89, p = .97).
Risk of Bias Across Studies (Quality Assessment)
Using the GRADE considerations, the quality of the primary and secondary outcomes was reported as either "low" or "very low" within a Summary of Findings table (see Table S3 , Supplemental Digital Content, http://links.lww.com/PSYMED/A498).
Subgroup Analyses
A subgroup analysis conducted for CHD participants found that a smaller proportion of those receiving CBT were still classified as depressed at follow-up, compared with controls (OR = 0.14, 95% CI = 0.06 to 0.30, p < .001, I
A significant difference in depression at follow-up (SMD = −0.29, 95% CI = −0.48 to −0.09, p = .003, I 2 = 4%) was observed in patients with ACS receiving CBT but not for anxiety (SMD = −0.16, 95% CI = −0.48 to 0.16, p = .34, I 2 = 0%). There was a significant reduction in depression at follow-up between CBT and control patients after face-to-face sessions (SMD = −0.48, 95% CI = −0.73 to −0.23, p < .001, I 2 = 60%) but not after telephone (SMD = −0.17, 95% CI = −0.57 to 0.23, p = . 40 
Sensitivity Analysis
Removal of participants with clinically diagnosed depression (29) did not significantly alter the primary outcomes (depression: SMD = −0.34, 95% CI = −0.56 to −0.12, p = .002; anxiety: SMD = −0.34, 95% CI = −0.65 to −0.03, p = .03; proportion remaining depressed: OR = 0.29, 95% CI = 0.12 to 0.69, p = .005).
Depression and anxiety at follow-up were attenuated and became nonsignificant when the US trials were excluded from the analyses (SMD = −0.12, 95% CI = −0.36 to 0.13, p = .36, I 2 = 25%; SMD = −0.12, 95% CI = −0.38 to 0.15, p = .38, I 2 = 0%). Removal of the ENhancing Recovery In Coronary Heart Disease patients trial (29) resulted in a marginal change in depression at follow-up, and it remained significant (SMD = −0.34, 95% CI = −0.56 to −0.12, p = .002, I 2 = 63%).
DISCUSSION
This is the first systematic review and meta-analysis to specifically investigate the effectiveness of CBT for anxiety and depression in CHD, ACS, AF, and post-MI patients. CBT significantly reduced both depression and anxiety and improved QoL compared with controls. However, substantial heterogeneity was present in the pooled anxiety follow-up scores, so these results should be interpreted with caution. CBT also significantly reduced the proportion of patients still depressed at follow-up, when compared with controls. However, there were no significant differences between CBT and control patients regarding cardiovascular events or patient satisfaction. This may be partly attributable to the lack of available data for these outcomes. Compared with controls, face-to-face CBT was the only mode of delivery to demonstrate statistically significant differences in anxiety and depression. Depression and anxiety were significantly reduced at all follow-up points.
With the known association between poor mental health and worse CVD outcomes (2), future studies should investigate the impact of CBT on cardiovascular mortality and events. A previous systematic review in patients with CHD found a small but nonsignificant effect of psychological interventions in reducing cardiac mortality (relative risk 0.80, 95% CI = 0.64 to 1.00, p = .56, I 2 = 0%) (20) . Previous reviews have also demonstrated beneficial effects of mixed psychological interventions in depressed patients with CHD (18) (19) (20) . Greater reductions in depression have been demonstrated in this review and may indicate the superiority of CBT to other psychological interventions. Unfortunately, other CVDs such as AF have received less research focus and only one included study recruited AF patients (33) . An on-going trial is currently investigating the effectiveness of CBT in AF patients with depression and/or anxiety (38) .
The benefit of face-to-face CBT over other methods may indicate the importance of personal and interactive sessions, and this should be considered in future CBT trials. Internet-based CBT alone was not investigated by any included study, so the individual effect could not be deduced. This method may provide a widely accessible and cheaper form of CBT although it may not be suitable for moderate-to-severe depression or anxiety. No study has investigated the effectiveness of Internet-based CBT in patients with CVD (post-MI, CHD, ACS, or AF) with depression and/or anxiety. However, an on-going trial, examining the effectiveness of Internet-based CBT in post-MI patients with depression and/or anxiety (39) , may indicate any potential benefit of Internet-based CBT in patients with CVD. Interestingly, depression and anxiety at follow-up were attenuated and nonsignificant after the removal of the US trials. When interpreting this finding, it is important to remember that 7/12 trials included within this review were conducted in the United States, and therefore, US patients represent the largest proportion (84%). The sensitivity analysis suggests that the US trials are driving the positive findings of CBT on a reduction in depression and anxiety. There may be country-specific differences in the experiences of patients and/or delivery of CBT, which influenced the results of these trials.
Reductions in depression were greatest at short-term follow-up, thus suggesting longer CBT courses may be required to maintain psychological well-being postintervention. Anxiety symptoms, however, were most improved at longterm follow-up. This could be explained by heightened anxiety regarding therapy completion and concerns of less therapist contact (14) .
This review has numerous strengths. A range of databases were searched without restrictions on language or timescales, authors supplied subgroup data, and the study selection process and RoB assessments were conducted independently by two reviewers. However, there was considerable heterogeneity between study participants, outcome scales, CBT content, and delivery, which may influence the findings.
There are some limitations to this review. Within studies, blinding participants to CBT is challenging and can be problematic when outcomes are self-reported. The participant's knowledge of their allocation could influence their responses and introduce social desirability bias. Four studies (25, 28, 29, 40 ) also had a high RoB for one or more of the remaining RoB tool domains. However, when assessed in a sensitivity analysis, removal of studies with a high RoB did not significantly affect the review's primary results. The review outcomes were assessed by GRADE as low or very low quality, which is partly attributable to the fact that the participants and personnel could not be blinded. However, other factors affecting outcome quality such as heterogeneity and differences in intervention delivery between studies could be overcome in future RCT trials by using similar outcome measures, methodology, and intervention delivery. As this review has suggested, at least 5 hours of CBT is necessary to reduce anxiety and depression in patients with CVD. Furthermore, long-term follow-up may be more valuable for identifying the effects of CBT on anxiety and depression. For some studies, only a specific sample of their participants were relevant to this review, which consequently created smaller sample sizes. Furthermore, subgroup analysis data were not available from all the studies (29) . Future RCTs should increase their sample sizes of CHD, ACS, AF, and post-MI patients to improve the quality of review outcomes.
This review supports the use of CBT as a first-line treatment for anxiety and depression in patients with CVD, as recommended by NICE (11, 12) . To maximize the benefit of this therapy, clinicians should prioritize face-to-face sessions and increase CBT duration. However, CBT is time-consuming and expensive; therefore, other methods may be required. On-going research may demonstrate the benefits of Internet-based sessions with the potential to lower CBT costs (39) . Previous research suggests that men and women with CHD respond differently to depression treatment (29) . However, no review within this field has assessed the effects of CBT on depression or cardiovascular outcomes by sex. Because of lack of access to data separately for men and women in half of the studies included in this review, an analysis by sex was not possible; however, future research should assess the sex differences in the effects of CBT and report findings by sex.
In conclusion, this review and meta-analysis supports the effectiveness of CBT in reducing anxiety and depression and improving QoL in patients with CVD, and indicates that this therapy should be considered by clinicians. However, considerable heterogeneity was present between studies and AF patients were poorly represented. Face-to-face CBT sessions seem to achieve the greatest patient benefit, and this should be considered when designing future studies. Furthermore, it is essential that cardiovascular outcomes are recorded to develop our understanding of the impact of CBT on CVD prognoses.
